Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Truscreen Group Limited, along with its various subsidiaries, specializes in the design, production, and distribution of innovative cancer detection equipment and systems. The company's market presence extends globally, covering regions such as Mexico, China, Russia, Vietnam, Zimbabwe, Eastern Europe, and the Middle East/North Africa, among other international territories. Central to its offerings is the TruScreen cervical cancer screening system, a sophisticated medical device engineered to identify precancerous and cancerous tissue on the cervix with immediate, real-time results. Incorporated in 2013, the organization was originally known as TruScreen Limited before officially changing to Truscreen Group Limited in August 2020. Its corporate headquarters are situated in Auckland, New Zealand.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of TRU.AX is 0.02 and suggests 66.7% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in